Benitec Biopharma Inc. (BNTC) Balance Sheet
BNTC balance sheet, FY2026
June 30, 2026 · U.S. dollars$182.6M assets = $5.6M liabilities + $177.0M equity
Both columns are drawn to the same scale: what BNTC owns equals what it owes plus shareholders’ equity. Hover a block for its value.
BNTC financial health
Descriptive bands, not a rating. Fiscal FY2026.
BNTC balance sheet trends, FY2025–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $99.6MFY2025 | $182.6MFY2026 | +83.4%/yr | |
| Total liabilities | $2.3MFY2025 | $5.6MFY2026 | +144.2%/yr | |
| Shareholders’ equity | $97.3MFY2025 | $177.0MFY2026 | +81.9%/yr | |
| Cash & short-term investments | $97.7MFY2025 | $180.0MFY2026 | +84.1%/yr | |
| Total debt | $849,000FY2025 | $762,000FY2026 | −10.2%/yr | |
| Net cash (debt) | $96.9MFY2025 | $179.2MFY2026 | +$82.3M | |
| Working capital | $96.7MFY2025 | $176.3MFY2026 | +$79.6M | |
| Book value per share | $2.69FY2025 | $3.80FY2026 | +41.5%/yr | |
| Debt / equity | 0.01FY2025 | 0.00FY2026 | 0.00 | |
| Shares outstanding | 36.2MFY2025 | 46.6MFY2026 | +28.6%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
BNTC assets
BNTC liabilities and equity
BNTC debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
BNTC balance sheet
| FY2026 | FY2025 | |
|---|---|---|
| Assets | ||
| Cash & short-term investments | $180.0M | $97.7M |
| Cash & equivalents | $180.0M | $97.7M |
| Receivables | $4,000 | $33,000 |
| Inventory | $0 | $0 |
| Other current assets | $1.7M | $741,000 |
| Total current assets | $181.7M | $98.5M |
| Property, plant & equipment (net) | $871,000 | $991,000 |
| Goodwill & intangible assets | $0 | $0 |
| Long-term investments | $0 | $0 |
| Other non-current assets | $67,000 | $83,000 |
| Total assets | $182.6M | $99.6M |
| Liabilities | ||
| Accounts payable | $913,000 | $201,000 |
| Short-term debt | $496,000 | $354,000 |
| Total current liabilities | $5.3M | $1.8M |
| Long-term debt | $0 | $0 |
| Lease obligations | $762,000 | $849,000 |
| Other long-term liabilities | $266,000 | $495,000 |
| Total liabilities | $5.6M | $2.3M |
| Shareholders' equity | ||
| Common stock & paid-in capital | $3,000 | $2,000 |
| Retained earnings (deficit) | −$273.7M | −$228.2M |
| Accumulated other comprehensive income | −$963,000 | −$839,000 |
| Total shareholders' equity | $177.0M | $97.3M |
| Key figures | ||
| Total debt | $762,000 | $849,000 |
| Net cash (debt) | $179.2M | $96.9M |
| Working capital | $176.3M | $96.7M |
| Tangible book value | $177.0M | $97.3M |
| Book value per share | $3.80 | $2.69 |
| Shares outstanding | 46.6M | 36.2M |
| Current ratio | 34.00 | 54.67 |
| Quick ratio | 33.68 | 54.26 |
| Debt / equity | 0.00 | 0.01 |
| Equity / assets | 96.9% | 97.7% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | |
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Cash & short-term investments | $180.0M | $184.8M | $188.8M | $94.5M | $97.7M | $103.6M | $78.3M |
| Cash & equivalents | $180.0M | $184.8M | $188.8M | $94.5M | $97.7M | $103.6M | $78.3M |
| Receivables | $4,000 | $3,000 | $130,000 | $7,000 | $33,000 | $3,000 | $2,000 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $1.7M | $1.3M | $675,000 | $593,000 | $741,000 | $424,000 | $428,000 |
| Total current assets | $181.7M | $186.0M | $189.6M | $95.1M | $98.5M | $104.0M | $78.7M |
| Property, plant & equipment (net) | $871,000 | $916,000 | $1.0M | $873,000 | $991,000 | $1.1M | $288,000 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $67,000 | $67,000 | $66,000 | $75,000 | $83,000 | $90,000 | $67,000 |
| Total assets | $182.6M | $187.0M | $190.7M | $96.0M | $99.6M | $105.2M | $79.1M |
| Liabilities | |||||||
| Accounts payable | $913,000 | $635,000 | $1.0M | $271,000 | $201,000 | $433,000 | $593,000 |
| Short-term debt | $496,000 | $482,000 | $468,000 | $414,000 | $354,000 | $346,000 | $137,000 |
| Total current liabilities | $5.3M | $3.3M | $2.8M | $2.0M | $1.8M | $7.0M | $3.1M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $762,000 | $876,000 | $987,000 | $817,000 | $849,000 | $959,000 | $137,000 |
| Other long-term liabilities | $266,000 | $394,000 | $519,000 | $403,000 | $495,000 | $613,000 | $38,000 |
| Total liabilities | $5.6M | $3.7M | $3.3M | $2.4M | $2.3M | $7.6M | $3.1M |
| Shareholders' equity | |||||||
| Common stock & paid-in capital | $3,000 | $3,000 | $3,000 | $2,000 | $2,000 | $2,000 | $2,000 |
| Retained earnings (deficit) | −$273.7M | −$260.9M | −$249.0M | −$237.1M | −$228.2M | −$212.0M | −$202.7M |
| Accumulated other comprehensive income | −$963,000 | −$952,000 | −$883,000 | −$750,000 | −$839,000 | −$716,000 | −$688,000 |
| Total shareholders' equity | $177.0M | $183.3M | $187.4M | $93.6M | $97.3M | $97.6M | $75.9M |
| Key figures | |||||||
| Total debt | $762,000 | $876,000 | $987,000 | $817,000 | $849,000 | $959,000 | $137,000 |
| Net cash (debt) | $179.2M | $183.9M | $187.8M | $93.7M | $96.9M | $102.6M | $78.1M |
| Working capital | $176.3M | $182.7M | $186.8M | $93.1M | $96.7M | $97.0M | $75.6M |
| Tangible book value | $177.0M | $183.3M | $187.4M | $93.6M | $97.3M | $97.6M | $75.9M |
| Book value per share | $3.80 | $3.71 | $4.08 | $2.25 | $2.69 | $2.53 | $3.44 |
| Shares outstanding | 46.6M | 49.4M | 46.0M | 41.5M | 36.2M | 38.6M | 22.1M |
| Current ratio | 34.00 | 56.82 | 67.69 | 46.95 | 54.67 | 14.80 | 25.48 |
| Quick ratio | 33.68 | 56.43 | 67.45 | 46.66 | 54.26 | 14.74 | 25.34 |
| Debt / equity | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
| Equity / assets | 96.9% | 98.0% | 98.3% | 97.5% | 97.7% | 92.7% | 96.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed September 14, 2026); data from EODHD.
BNTC financial position
At the end of fiscal 2026 (June 30, 2026), Benitec Biopharma had total assets of $182.6 million (up 83.4% from a year earlier), total liabilities of $5.6 million and shareholders' equity of $177.0 million. It held $180.0 million in cash and short-term investments against $0.8 million of debt, a net cash position of $179.2 million. Its current ratio was 34.00.
Related: BNTC income statement, BNTC cash flow statement, BNTC key metrics. See the BNTC stock overview for the latest quote and news.
BNTC balance sheet FAQ
What are Benitec Biopharma's total assets?
Benitec Biopharma reported total assets of $182.6 million at the end of fiscal 2026 (June 30, 2026), compared with $99.6 million a year earlier.
How much debt does Benitec Biopharma have?
Benitec Biopharma had $0.8 million of total debt at the end of fiscal 2026, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.00.
How much cash does Benitec Biopharma have?
Benitec Biopharma held $180.0 million in cash and short-term investments at the end of fiscal 2026; with $0.8 million of debt that is net cash of $179.2 million.
What is Benitec Biopharma's book value?
Benitec Biopharma's shareholders' equity (book value) was $177.0 million at the end of fiscal 2026, or $3.80 per share.
What is Benitec Biopharma's current ratio?
Benitec Biopharma had current assets of $181.7 million and current liabilities of $5.3 million, a current ratio of 34.00 (it can cover its short-term obligations).